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Bipolar disorder (BD) is a severe mental disorder characterized by recurrent episodes of mania and depression. Serotonin
transporter (HTT) is a target of antidepressants and is one of the strongest candidate molecules of mood disorder, however,
genetic study showed equivocal results. Here, we performed promoter-wide DNA methylation analysis of lymphoblastoid cell
lines(LCLs)derivedfromtwopairsofmonozygotictwinsdiscordantforBD.Toruleoutthepossiblediscordanceofcopynumber
variation(CNV)betweentwins,weperformedCNVanalysisandfoundthecopynumberproﬁleswerenearlyidenticalbetweenthe
twinpairsexceptforimmunoglobulin-relatedregions.Amongthethreegenesweobtainedascandidateregionsshowingdistinct
difference of DNA methylation between one of the two pairs, hypermethylation of SLC6A4, encoding HTT, in the bipolar twin was
only conﬁrmed by bisulﬁte sequencing. Then, promoter hypermethylation of SLC6A4 in LCLs of BD patients was conﬁrmed in a
case–control analysis. DNA methylation of SLC6A4 was signiﬁcantly correlated with its mRNA expression level in individuals
with the S/S genotype of HTTLPR, and mRNA expression level was lower in BD patients carrying the S/S genotype. Finally,
DNAmethylationofthesamesitewasalsohigherinthepostmortembrainsofBDpatients.Thisistheﬁrststudytoreporttherole
of epigenetic modiﬁcation of SLC6A4 in BD using an unbiased approach, which provides an insight for its pathophysiology.
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Introduction
Mood disorders such as major depression and bipolar
disorder (BD) cause severe social burdens and there is an
urgent need to elucidate the pathophysiology of these
disorders. Studying the mechanisms of action of psychotropic
drugs has been a major strategy to understand the patho-
physiology of mental disorders, and research has focused on
serotonin transporter (HTT), the target molecule of anti-
depressants. Altered density of HTT in the brains of patients
with mood disorders has been reported in postmortem
samples
1 and by in vivo molecular imaging.
2–6 A serotonin-
transporter-linked promoter region (HTTLPR) includes the
functional polymorphism, in which the short (S) allele has
lower promoter activity than the long (L) allele,
7 and it has
been implicated in mood disorders.
1,8–10 The S allele was
reported to bea risk factor formood disorders, interacting with
stress and/or early environment.
8 However, the results of
subsequentstudies areconﬂicting
11–13andnone oftherecent
genome-wide association studies supported the role of
SLC6A4 in mood disorders.
14
We have been searching for gene expression and
epigenetic differences between monozygotic (MZ) twins
discordant for BD to elucidate the molecular pathways
relevant to its pathophysiology.
15,16 Although high concor-
dance rate of BD in MZ twins supports the contribution of
genetic factor in BD, importantly, it is not 100%. Because MZ
twins have been regarded ashaving identical genomes,these
facts suggest the importance of environmental or epigenetic
factor for the onset of mental disorders. In fact, considerable
epigenomic differences between MZ twins have been
reported by several groups.
17–22 On the other hand,
there are also reports of genomic differences between MZ
twins such as point mutations,
23–25 microsatellite repeat
length
26 and copy number variations (CNVs).
27 Therefore,
both genetic and epigenetic factors may have a role in the
discordance of the onset of diseases between MZ twins.
Here, we performed promoter-wide DNA methylation
analysis of lymphoblastoid cell lines (LCLs) derived from two
pairs of MZ twins discordant for BD. To rule out the possible
discordance of CNV between twins, we performed CNV
analysis.
Materials and methods
Samples. We enrolled two pairs of MZ twins discordant
with respect to BD (Supplementary Table S1). The twins
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www.nature.com/tpwere 49-year-old males (pair 1, previously reported in
Kusumi et al.
28) and 42-year-old males (pair 2). Detailed
clinical information was described in previous reports and
their zygosities were determined by micro-satellite markers
and single nucleotide polymorphisms.
15,16 We used their
genomic DNA derived from LCLs for all analyses.
In the CNV analysis, we used a female sample (NA15500,
Coriell Cell Repository, Camden, NJ, USA) as a reference
and an unrelated healthy female sample for quality control
of real-time PCR analysis. Methods of CNV analysis are
shown in Supplementary Information.
To exclude the genomic regions in which DNA methylation
is different between peripheral blood leukocytes (PBLs) and
LCLs, we used four sets of PBLs and LCLs from the same
individuals who were unrelated healthy Japanese males and
females.
29 For the collection of PBLs, blood was collected
into a 7ml tube containing EDTA. Red blood cells were lysed
by osmotic shock by adding 40ml of red blood cell lysis
buffer containing 10mM Tris/HCl, pH 7.6, 6mM MgCl2 and
10mM NaCl. After centrifugation, the pellet was used for DNA
extraction.
For the case–control analysis, we examined 20 unrelated
BD patients (12 males and 8 females, 38.8±13.1 years old
(mean±s.d.)) and 20 unrelated control subjects (16 males
and 4 females, 38.5±8.9 years old) using their genomic DNA
derived from LCLs. They were subjects from our previous
report,
30 and all of them were Japanese. Written informed
consent was obtained from all the subjects.
Postmortem prefrontal cortices (BA10) derived from BD
patients (N¼35) and controls (N¼35) were provided by the
Stanley Foundation Brain Collection (The Stanley Medical
Research Institute, Chevy Chase, MD, USA). We were able
to use 31 BD samples and 32 control samples for DNA
methylation analysis.
This study was approved by the Research Ethics
Committee of RIKEN.
Cell cultures. LCLs were previously established by
transforming the lymphocytes with Epstein–Barr (EB) virus
following standard protocol.
31 Brieﬂy, lymphocytes were
separated from peripheral blood and cultured with RPMI
1640 medium containing 20% fetal bovine serum (Gibco,
Carlsbad, CA, USA), penicillin and streptomycin (50mgml
 1
each) and supernatant of the B95-8 cell culture infected by
the EB virus. After the cells showed stable growth, they were
passaged two or three times a week using similar medium
except for 10% fetal bovine serum. The cells were then
kept frozen and recultured for the experiment. We used
low-passage LCLs for case–control studies. Genomic DNA
was extracted using Gentra Puregene Cell kit (Qiagen,
Hilden, Germany).
DNA methylation analysis
Enrichment of methylated DNA. We used a MethylCollector
Ultra Kit (Active Motif, Carlsbad, CA, USA), which can enrich
methylated DNA fragments with as few as ﬁve methylated
CpG sites. DNA fragments (100ng) were sonicated to
produce 100- to 300-bp fragments using a sonicator
(Covaris, Woburn, MA, USA) and they were incubated with
a His-tagged recombinant MBD2b/MBD3L1 protein complex.
After stringent washing, methylated DNA was eluted and
puriﬁed using the MiniElute PCR puriﬁcation kit (Qiagen).
Promoter tiling array. We used a GeneChip Human
Promoter 1.0R array (Affymetrix, Santa Clara, CA, USA),
which contains 4.6 million probes tiled to cover more than
25500 human promoter regions. Sample preparation for the
tiling array was performed according to the Affymetrix
chromatin immunoprecipitation assay protocol provided by
the manufacturer. Brieﬂy, after ampliﬁcation, DNA samples
were labeled using a GeneChip WT Double-Stranded
DNA Terminal Labeling Kit (Affymetrix), and they were
then hybridized with Affymetrix GeneChip Human Promoter
1.0R arrays. The arrays were stained and washed
using GeneChip Fluidics Station 450 and scanned with
the GeneChip 3000 7G Scanner. We used fully CpG
unmethylated DNA obtained by whole genome ampliﬁcation
as a reference sample.
Tiling array data analysis. For the detection of methylated
regions (MRs), model-based analysis of tiling arrays (MAT)
software was used.
32 By using MAT, the signals of each
probe in each array can be standardized individually.
Parameters used in the MAT analysis were as follows:
bandwidth, 300; maximum gap, 300; minimum number of
probes, 10; P value, 10
 4.
The ﬁltering process was performed with R script (http://
www.r-project.org) using the following steps (Supplementary
Figure S4). Scripts are available upon request.
(1) Data of each twin pair were directly compared. The
regions showing signiﬁcant differences between the BD
twin and the healthy co-twin were selected. Only those
regions containing six or more CpG sites were further
selected because the MethylCollector can collect only the
DNA fragments that contain ﬁve or more CpG sites. The
selected MRs were named BD (bipolar twin)-dominant
MRs and C (healthy co-twin)-dominant MRs.
( 2 )T h ed a t ao fe a c ht w i nw e r ec o m p a r e dw i t ht h o s eo fa
reference sample (that is, unmethylated DNA). Among the
BD-dominant MRs, the regions showing the signiﬁcantly
methylated signal compared with a reference sample in BD
twin but not in healthy co-twin were selected. The selected
regions were named BD-speciﬁc MRs. C-speciﬁc MRs
were determined vice versa. This step highlighted the
methylation difference between twins and eliminates
signiﬁcant but subtle differences to maximize the chance
for successful conﬁrmation by other methods.
(3) The MRs overlapping with a CpG islands were selected.
Forvalidationoftilingarraydata,wearbitrarilyselected13
representative MRs for bisulﬁte sequencing.
Bisulﬁte conversion. Either 2mg (for LCL samples) or 500ng
(for postmortem brain samples) of genomic DNA was
converted for methylation sequencing using Epitect bisulﬁte
kits (Qiagen), according to the manufacturer’s standard
protocol. Completion of sodium bisulﬁte conversion was
conﬁrmed during sequencing by ensuring that known lone
cytosines were read as thymines.
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Translational PsychiatryBisulﬁte sequencing. Primer pairs were determined using
Meth Primer software.
33 PCR products were puriﬁed by
MinElute PCR Puriﬁcation Kit (Qiagen) or digested with
thermostable b-agarase (NIPPON GENE, Tokyo, Japan) and
cloned using a TOPO TA cloning kit (Invitrogen, Carlsbad,
CA, USA). Single bacterial colonies were subjected to
sequencing analysis. Each bisulﬁte sequencing data was
quantiﬁed by quantiﬁcation tool for methyaltion analysis.
34
Filtering of tiling array data. To further narrow the number of
MRs by setting more stringent criteria based on the results
of bisulﬁte sequencing, we reset the threshold for ﬁltering as
a P value o10
 6 of direct comparison between each twin
pair (Supplementary Figure S5, step 4).
Next, we excluded the regions that showed alteration of
DNAmethylationstatusbeforeandafterthetransformationby
EB virus. We previously performed the DNA methylation
analysis using the same platform in four sets of PBLs and
LCLs established from the same individuals and identiﬁed the
regions that showed methylation only in LCLs or only in
PBLs.
30 MRs that overlapped with those regions were
excluded (Supplementary Figure S5, step 5).
Finally, from the candidate regions forBD-speciﬁc MRs, the
regions that were detected as MRs in at least one of LCL were
excluded (Supplementary Figure S4), because the regions
methylated in LCLs of healthy individuals cannot be related to
disease. With regard to the C-speciﬁc MRs, only the regions
overlapping with common MRs in four LCLs were selected.
Loss of methylation in patients can be regarded as related to
disease only when methylation in that region is consistently
seeninhealthyindividuals(SupplementaryFigureS5,step6).
Case–control analysis
Pyrosequencing. The PCR product of bisulﬁte-modiﬁed DNA
was used for pyrosequencing analysis according to the
manufacturer’s standard protocol (Qiagen). Brieﬂy, 4mlo f
streptavidin-sepharose beads (Amersham Biosciences,
Piscataway, NJ, USA) and 54ml of binding buffer (10mM
Tris-HCl, 1mM EDTA, 2 M NaCl, 0.1% Tween-20 at pH 7.6)
were mixed with 50ml of PCR product for 10min at room
temperature. The reaction mixture was placed onto a
MultiScreen-HV, Clear Plate (Millipore, Billerica, MA, USA).
After applying the vacuum, the beads were treated with a
denaturation solution (0.2 N NaOH) for 1min and washed
twice with washing buffer (10mM Tris-acetate at pH 7.6). The
beads were then suspended with 50ml of annealing buffer
(20mM Tris-acetate, 2mM Mg-acetate at pH 7.6) containing
10pmol of sequencing primer. The template-sequencing
primer mixture was transferred onto a PSQ 96 Plate
(Biotage, Uppsala, Sweden), heated to 901C for 2min and
cooled to room temperature. Sequencing reactions were
performed with a PyroMark Gold Q96 Reagents Kit (Qiagen)
according to the manufacturer’s instructions. The
percentages of methylation were calculated from the raw
data using the allele quantiﬁcation algorithm of the software
provided by the manufacturer (PSQ96MA2.1.1 software,
Qiagen).
35 The PCR primers used for bisulﬁte sequencing of
the promoter region of SLC6A4 were 50-TTTTTAGTTGTTTG
GGTATTTGTGTTA-30 (forward) and 50-AAAACTTTACAAC
CTCTTAAAAACCC-30 (reverse). The sequencing primers
were 50-TTTTGTATAAAGTTATTTGT-30,5 0-AATATAAATTA
TGGGTTGAA-30 and 50-ATTTTTTTTAAGGGGTTTTT-30,
and the reading sequences were AT/CGT/CAT, AT/CGA
AAGTAAGTAATTTTTTTTAAAGT/CG and TAT/CGG.
Genotyping. Using genomic DNA derived from LCLs, we
investigated the length polymorphism repeat (HTTLPR) in
the promoter region of SLC6A4, which comprises a 44-bp
insertion (long, L allele) or deletion (short, S allele), and one
single nucleotide polymorphism in L allele (LA/LG), which
was reported to be related to gene expression as well as
HTTLPR genotype.
36
For HTTLPR genotype analysis, ampliﬁcation of genomic
DNA was performed as initially described by Kaiser et al.,
37,38
with slight modiﬁcations. In a total volume of 10ml, we used
40ng DNA; 200mM each of dATP, dCTP, and dTTP; 150mM
dGTP, 50mM; 7-deaza-GTP (Roche, Mannheim, Germany);
1mM of each primer; 10* buffer 1; and 2.8 units of mixed
polymerase (Taq- and Tgo-polymerase) from the Expand
Long-Range PCR System (Roche). Applied primer
sequences were 50-GCAACCTCCCAGCAACTCCCTGTA-30
(forward) and 50-GAGGTGCAGGGGGATGCTGGAA-30
(reverse). The PCR program of both reactions consisted of
an initial cycle of 2min at 941C followed by 35 cycles each
consisting of 10s at 981C, 30s at 681C and 30s at 721C.
After ampliﬁcation, HTTLPR amplicons were separated by
electrophoresis in 3% agarose gels after staining with
ethidium bromide.
For LA/LG single nucleotide polymorphism analysis, each
product of L allele in L/S genotype subjects was digested with
thermostable b-agarase (NIPPON GENE) and subjected to
sequencing analysis.
Real-time quantitative RT-PCR. Total RNA was extracted
using Trizol (Invitrogen) and cleaned following the standard
protocol. After DNase I treatment, 5mg of total RNA was
used for complementary DNA synthesis by oligo (dT) 12–18
primer and SuperScript II reverse transcriptase (Invitrogen).
Real-time quantitative RT-PCR using Taqman Universal
PCR master mix, No AmpErase UNG (Applied Biosystems,
a part of Life Technologies, Carlsbad, CA, USA), was per-
formed with an ABI Prism 7900HT (Applied Biosystems).
The PCR conditions were denaturation at 951C for
10min, followed by 40 cycles of 951C for 15s and 601C
for 60s. The comparative Ct method was used to quantify
transcripts according to the manufacturer’s protocol (User
Bulletin 2, Applied Biosystems). Each sample was quantiﬁed
in triplicate. Ampliﬁcation of single products was conﬁrmed
by monitoring the dissociation curve. We used the expres-
sion level of actin beta (ACTB) as an internal control. The
standard ABI primer probe sets were used (SLC6A4,
Hs00984356; ACTB, Hs99999903). We performed statis-
tical analysis using SPSS (SPSS Japan, Tokyo, Japan).
Results
Copy number differences between the twins. The copy
number proﬁles were seemingly identical between both twin
pairs (Supplementary Figure S1). To ﬁnd subtle copy number
differences between the twins, we detected their respective
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calculated the fold change of each probe. In both twin
pairs, the differences with fold changes of more than 1.2
were mostly found on chromosomes 2, 14 and 22, which
contain immunoglobulin (Ig)-related regions (Supplementary
Figure S2). We examined 40 regions including one Ig-related
region by real time PCR analysis. Although the copy number
change of Ig-related region was conﬁrmed, none of other
regions with copy number differences between the twins
were conﬁrmed by real-time PCR analysis (Supplementary
Figure S3). This suggested that most of the apparent copy
number differences detected by the array were false
positives, except for Ig-related regions. The differences
of the copy number in Ig-related regions between the twins
are reasonable because a single B cell having a speciﬁc
genome rearrangement of Ig-related gene
39 is ampliﬁed by
EB virus transformation in LCLs.
DNA methylation differences between the twins. Promoter-
wide DNA methylation proﬁles of the twins were examined by
Affymetrix GeneChip Human Promoter 1.0R tilling arrays after
methylated DNA was enriched using MBD2b and MBD3L1
conjugated beads. Fully unmethylated DNA obtained by whole
genome ampliﬁcation was used as a reference. Using this
method, the DNA methylated status within the 10kb range
for each of more than 25500 promoters could be analyzed.
MAT
32 was used to identify MRs. By using MAT, the signals of
each probe in each array can be standardized individually.
DNA methylation analysis by the promoter tiling array
showed MRs speciﬁc to the bipolar twin (80 or 4, respectively)
or those to the healthy co-twin (71 or 81, respectively) in each
twin pair (Supplementary Figure S4). Among the 236 regions
containing six or more CpG sites, 13 representative regions
overlapping with CpG islands were analyzed by bisulﬁte
sequencing to validate the tiling array data. Although the DNA
methylation differences between the twins were conﬁrmed in
most regions, some differences with P values more than 10
 6
couldnotbeconﬁrmed(SupplementaryFiguresS5andS6).To
narrow the number of candidate MRs, we applied more
stringent criteria (P value p10
 6) based on the results of
bisulﬁtesequencing.WecomparedtheDNAmethylationstatus
between four sets of PBLs and LCLs obtained from the same
individuals and found that MRs in PBLs were largely conserved
in LCLs but a part of the regions were methylated only in LCLs
or only in PBLs.
30 Thus, we eliminated those ‘variable’ MRs
during establishment of LCLs. Furthermore, the regions
detected as MRs in at least one of the LCL were excluded
from the BD-speciﬁc MRs, and only the regions overlapping
withcommonMRsinfourLCLswereselectedwithregardtothe
C-speciﬁcMRs(SupplementaryFigureS4).Weﬁnallyobtained
three candidate MRs: KIAA1530 on chromosome 4 as a
hypermethylated region in the healthy co-twin, and FANK1
(ﬁbronectin type III and ankyrin repeat domains 1) on
chromosome 10 and SLC6A4, encoding serotonin transporter
on chromosome 17 (Supplementary Figure S7), as a hyper-
methylated region in the bipolar twin, only from pair 1.
These three regions were examined by bisulﬁte sequen-
cing, and we could conﬁrm the differential DNA methylation
status between the twins only in the promoter region of
SLC6A4 (Figure 1b and Supplementary Figures S8 and S9).
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Figure 1 DNA methylation difference between twins in SLC6A4.( a) Results of
comprehensive DNA methylation analysis of lymphoblastoid cell lines (LCLs) of a
pair of monozygotic twins discordant for bipolar disorder using tiling arrays. The
vertical axis represents the signal intensity, and the horizontal axis represents the
base number on the chromosome 17 (NCBI36/hg18). Exon–intron structure of the
SLC6A4isshown belowthedata oftiling arrays.TheCpGislandandtheregionsof
HTTLPR are shown by a green square and an arrow, respectively. The region
showing statisticallysigniﬁcant methylation differencebetweenthe bipolar twin and
thehealthyco-twin,andtheregionexaminedbybisulfatesequencingareshownby
a blue square and a red bar, respectively. (b) Results of bisulﬁte sequencing. The
genomic region examined by bisulﬁte sequencing, which corresponds to the base
numbers from 25586333 and 25586482, is shown above. The ﬁve CpG sites are
surrounded by red squares. Black and white circles represent the methylated and
unmethylated CpGs, respectively. Each raw shows the data of one clone.
Five circles in one raw represent the ﬁve CpG sites shown above. This region is
methylated in the bipolar twin but not in the healthy co-twin. (c) Representative
results of pyrosequencing using independent samples. The results of two CpG
sites (3 and 4) were shown by yellow shadows. Percentages of C and T mean
fractions of methylation and unmethylation on each CpG site, respectively. Each
fraction of methylation on other CpG sites of the bipolar twin and the healthy co-
twin was 24.2 and 0 on CpG1, 28.8 and 0 on CpG2, and 9.3 and 4.3 on CpG5,
respectively. The differences of DNA methylation in SLC6A4 between the twins
were conﬁrmed using the other LCL samples of the twins recultured for this
experiment.
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downstream of HTTLPR was hypermethylated in the bipolar
twin. We also examined the DNA methylation status of the
twinsusingindependentcellculturebypyrosequencingtorule
out a possibility of cell culture-induced artiﬁcial or stochastic
change (Figure 1c).
Case–control analysis for DNA methylation of LCLs in
SLC6A4. Because there are DNA methylation changes
even between healthy MZ twins, the existence of DNA
methylation difference does not warrants the relationship
with the disease. Thus, we next performed a case–control
analysis using the LCLs of 20 patients with BD and 20
controls. The DNA methylation of the two CpG sites (CpG3
and CpG4) was signiﬁcantly higher in BD patients than
in controls (Po0.05, Mann–Whitney U-test; Figure 2a). We
also analyzed the expression level of SLC6A4 in LCLs by
real-time quantitative RT-PCR. HTTLPR, including a single
nucleotide polymorphism in L allele (LA/LG) that reportedly
affects gene expression, was genotyped.
36 Because all
subjects with L allele, but one control subject with S/LG
genotype, had LA allele, LA and LG alleles were not
separately analyzed. Among the subjects with the S/S
genotype, the mRNA expression level was signiﬁcantly
lower (Po0.05, Mann–Whitney U-test; Figure 2b) and the
DNA methylation level of CpG3 was signiﬁcantly higher
(Po0.05; Mann–Whitney U-test; Figure 2c) in the BD
patients compared with controls. The same trend was
seen in CpG4 (P¼0.059, Mann–Whitney U-test). The DNA
methylation level of CpG3 was signiﬁcantly correlated with its
mRNA expression level only in subjects with the S/S
genotype (r¼ 0.425, P¼0.043, n¼23; Figure 2d) and not
in those with the S/L genotype (r¼ 0.262, P¼0.346,
n¼15; Figure 2e).
DNA methylation status of postmortem brain samples in
SLC6A4. DNA methylation patterns in blood cells may not
directly reﬂect the status of the brain. To test whether
hypermethylation of SLC6A4 is also observed in the
brain, we examined the DNA methylation status of these
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Figure 2 Case–control analysis of DNA methylation and gene expression in LCLs. (a) DNA methylation levels of ﬁve CpG sites shown in the Figure 1 in LCLs (bipolar
disorder (BD), n¼20, controls, n¼20) using pyrosequencing. Two CpG sites (3 and 4) showed signiﬁcantly higher DNA methylation in BD patients. Values indicate
mean±s.d. Asterisk indicates signiﬁcance; P¼0.008 and P¼0.035 for CpG3 and CpG4, respectively, by Mann–Whitney U test. (b) Relationship between expression level
of SLC6A4 and HTTLPR genotype (BD, n¼19, controls, n¼19). One datum in each diagnostic group was turned out to be at outlier by Smirnov–Grubbs test and removed
from data analysis. Among the all samples (n¼38), the mRNA level of SLC6A4 tended to be lower in BD patients compared with controls (P¼0.08; Mann–Whitney U-test).
ThemRNAexpressionlevelwassigniﬁcantlylowerinBDpatientscomparedwithcontrolsonlyinsubjectswiththeS/Sgenotype(P¼0.007;Mann–WhitneyU-test)andnotin
those with the S/L genotype (P¼0.867; Mann–Whitney U-test). Values indicate mean±s.d. An asterisk indicates signiﬁcant difference (Po0.05). NS, not statistically
signiﬁcant. (c) Relationship between the DNA methylation of CpG3 and HTTLPR genotype (BD, n¼20, controls, n¼20). The DNA methylation of the CpG3 site was
signiﬁcantly higher in BDpatientscompared with controlsonly in thesubjects with the S/Sgenotype (P¼0.020,Mann–Whitney U-test) butnot in those with the S/Lgenotype
(P¼0.105, Mann–Whitney U-test). The DNA methylation of the CpG4 site also tended to be higher in BD patients compared with controls only in the subjects with the S/S
genotype (P¼0.052, Mann–Whitney U-test) and not in those with the S/L genotype (P¼0.279, Mann–Whitney U-test). Values indicate mean±s.d. (d, e) Correlation
between the DNA methylation at the CpG3 site and mRNA expression level of SLC6A4 (BD, n¼19, controls, n¼19). There was a signiﬁcant correlation in the subjects with
the S/S genotype (r¼ 0.425, P¼0.043, n¼23); (d), whereas no signiﬁcant correlation was found in the subjects with the S/L genotype (r¼ 0.262, P¼0.346, n¼15);
(e). Closed circles represent patients with BD and open circles represent control subjects.
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Translational Psychiatrytwo CpG sites in postmortem brains of 31 BD patients and
32 controls obtained from the Stanley Foundation Brain
Collection. CpG4 showed a signiﬁcantly higher DNA methyla-
tion level in BD patients compared with controls (Po0.05,
Mann–Whitney U-test, one-tailed), and CpG3 also showed
the same trend (P¼0.059, Mann–Whitney U-test, one-tailed;
Figure 3). There was no signiﬁcant effect of confounding
factors, such as gender, age, postmortem interval (hours),
brain pH and administration of antidepressants, on the DNA
methylation level of the two CpG sites.
Discussion
Multiple lines of evidence suggest the role of SLC6A4 in BD.
Although the results of serotonin transporter-binding potential
in BD patients are conﬂicting,
2–6 one of them reported the low
potential in the depressive state,
40 and less gene expression
of serotonin transporter in postmortem brains of depressed
suicide victims was also reported.
41 HTTLPR was initially
reportedtobeassociatedwithBD,thoughsubsequentstudies
show conﬂicting results.
9,42,43 Gene-environment (G E)
interaction
14andresultingepigeneticchanges
44mightexplain
the inconsistent results of genetic studies in mood disorder.
14
In this study, we found a possible interaction between
HTTLPR genotype and BD diagnosis on the DNA methylation
and mRNAexpressionlevelofSLC6A4.DNAmethylation level
of the CpG island upstream of SLC6A4 was reported to be
associated with environmental factors
45,46 and possibly with
HTTLPR genotype.
47 Weaver et al.
48 hypothesized that DNA
methylation plays a role as an epigenetic mark of G E
interaction, and they suggested that hypermethylation of the
promoter region of the glucocorticoid receptor gene asso-
ciated with poor maternal care causes stress vulnerability.
Hypermethylation of SLC6A4 in BD may reﬂect epigenetic
effect in G E interaction and contribute to the patho
physiology of BD.
In this study, we performed promoter-wide DNA methyla-
tion analysis and detected hypermethylation of SLC6A4 in the
bipolar twin. The differences of methylation patterns between
MZ twins may depend on age and difference of nurturing
environment,
18 and a twin study showed that the variation of
DNA methylation in SLC6A4 is attributable to unique environ-
mental factors rather than heritable factors.
49 It would be
important to elucidate the origin and timing of the methylation
changeinSLC6A4
50in thefuture study.Inthis study,only one
of the two twins showed marked difference of DNA methyla-
tion of SLC6A4. Considering the heterogeneity of BD, it is not
realistictopostulatethatallpatientswithBDarecausedbythe
same genetic or epigenetic factor. Thus, a close investigation
in a large series of well-characterized discordant twins
may provide a clue to understand the pathophysiology of
BD.
51 In this study, the difference between the groups was
relatively modest in case–control studies. There was a large
inter-individual difference of DNA methylation at CpG3 in
LCLs of patients with BD (9.2 to 51%), possibly reﬂecting the
heterogeneity of BD. In these analyses, we used genomic
DNA derived from LCLs cultured with drug-free medium to
minimize the effect of medication on DNA methylation.
Although none of BD patients were taking antidepressants
at the blood sampling, it is difﬁcult to know what the effects
of medications and co-morbid illnesses are on the methy-
lation signatures observed in these samples. Moreover,
we only examined a portion of the SLC6A4. Although DNA
methylation in LCLs is not the same as PBLs, MRs in
PBLs are largely maintained in LCLs.
30 In this study, we
excluded the MRs affected by EB virus transformation and
ﬁnally detected the hypermethylation of SLC6A4 in the brains
of BD patients. We could only examine the methylation of
SLC6A4 in prefrontal cortices, but further analysis of other
regions expressing high levels of HTT, such as dorsal raphe
nucleus, would be interesting.
In summary, we detected hypermethylation of SLC6A4
in BD, using an unbiased approach. DNA methylation of
SLC6A4 may be an epigenetic mark resulting from a G E
interaction that leads to the development of BD. Our ﬁndings
add a new insight to elucidate the pathophysiology of mood
disorder.
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